食管癌根治性放疗前后外周血CK19 mRNA变化的临床意义  

Clinical Significance of CK19 mRNA Alteration in Peripheral Blood of Esophageal Cancer Patients Treated with Radiotherapy

作　　者：薛金俊[1] 殷旭东[1] 袁昕[1] 汪瑞[1] 张正荣[1] 夏广鑫[1] 

机构地区：[1]扬州市第一人民医院肿瘤科,江苏扬州225009

出　　处：《现代生物医学进展》2011年第24期4925-4927,共3页Progress in Modern Biomedicine

摘　　要：目的:研究检测食管癌根治性放疗前后外周血中循环肿瘤细胞(circulating tumor cells,CTC)标记细胞角蛋白19(Cytokeratin19,CK19)mRNA的变化及其临床意义。方法:收集72例食管癌患者根治性放疗前后外周血,应用巢式RT-PCR检测CK19 mRNA的表达,分析其与放疗疗效及两年无进展生存(progerssion-free survival,PFS)的关系。结果:放疗前后CK19 mRNA阳性者分别占44.4%(32/72)与30.6%(22/72),差别无统计学意义(P=0.085)。放疗前32例表达阳性者,放疗后其中12例转阴(37.5%),20例持续阳性(62.5%);40例阴性者,2例转为阳性(5.0%),38例持续阴性(81.2%)。并且,放疗前后CK19 mRNA变化与放疗疗效相关,放疗后CK19 mRNA阳性提示2年无进展生存期较差。结论:食管癌根治性前后外周血CK19 mRNA变化对于判断放疗疗效及预后具有重要意义。Objective： To study the clinical significance of the marker of circulating tumor cells（CTC）,cytokeratin 19（CK19） ex-pression in peripheral blood of esophageal cancer patients treated with radiotherapy.Methods： CK19 mRNA expression was determined using nest RT-PCR in pre-and post-radiotherapy blood of 72 esophageal cancer patients,its associations with radiotherapy response and 2-year progression-free survival（PFS） were further evaluated.Results： The positive expression of CK19 mRNA in pre-and post-radio-therapy were 44.4%（32/72） and 30.6%（22/72）,respectively,the difference was not statistical significance（P=0.085）.Besides,37.5%（12/32） of patients with initially CK-19 mRNA-positive turned negative while 62.5%（20/32） kept positive after radiotherapy,5.0%（2/40） of patients with initially CK-19 mRNA-negative turned positive while 95.0%（38/40） kept negative after radiotherapy.Furthermore,the alteration of pre-and post-radiotherapy CK19 mRNA expression was associated with radiotherapy response,and post-radiotherapy CK19 mRNA expression predicted adverse 2-yaar PFS.Conclusion： The alteration of pre-and post-radiotherapy CK19 mRNA expression maybe a useful biomarker related to radiotherapy response and prognosis of esophageal cancer patients treated with radiotherapy.

关 键 词：食管癌 放疗 细胞角蛋白19 预后 分子标记 

分 类 号：R735.1[医药卫生—肿瘤]